Evidence map›Paper›PMID 26167081›Full record

ArticleWorld journal of gastroenterology2015

miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan.

Tünde Halász, Gábor Horváth, Gabriella Pár, Klára Werling, András Kiss, Zsuzsa Schaff, Gábor Lendvai

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Trial
  2. International journal of molecular sciences · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. miR-122-5p Regulates Renal Fibrosis In Vivo.International journal of molecular sciences · 2022
    Article
  11. Review
  12. Review
  13. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA.International journal of molecular sciences · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Article
  18. Article
  19. MicroRNA (Shariqah, United Arab Emirates) · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tünde HalászTünde Halász, András Kiss, Zsuzsa Schaff, Gábor Lendvai, Second Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
Gábor HorváthTünde Halász, András Kiss, Zsuzsa Schaff, Gábor Lendvai, Second Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
Gabriella PárTünde Halász, András Kiss, Zsuzsa Schaff, Gábor Lendvai, Second Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
Klára WerlingTünde Halász, András Kiss, Zsuzsa Schaff, Gábor Lendvai, Second Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
András KissTünde Halász, András Kiss, Zsuzsa Schaff, Gábor Lendvai, Second Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
Zsuzsa SchaffTünde Halász, András Kiss, Zsuzsa Schaff, Gábor Lendvai, Second Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
Gábor LendvaiTünde Halász, András Kiss, Zsuzsa Schaff, Gábor Lendvai, Second Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate whether expression of selected miRNAs obtained from fibrotic liver biopsies correlate with fibrosis stage.

methodsAltogether, 52 patients were enrolled in the study representing various etiologic backgrounds of fibrosis: 24 cases with chronic hepatitis infections (types B, C), 19 with autoimmune liver diseases (autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, overlapping syndrome cases), and 9 of mixed etiology (alcoholic and nonalcoholic steatosis, cryptogenic cases). Severity of fibrosis was determined by both histologic staging using the METAVIR scoring system and noninvasive transient elastography. Following RNA isolation, expression levels of miR-21, miR-122, miR-214, miR-221, miR-222, and miR-224 were determined using TaqMan MicroRNA Assays applying miR-140 as the reference. Selection of miRNAs was based on their characteristic up- or downregulation observed in hepatocellular carcinoma. Relative expression of miRNAs was correlated with fibrosis stage and liver stiffness (LS) value measured by transient elastography, as well as with serum alanine aminotransferase (ALT) level.

resultsThe expression of individual miRNAs showed deregulated patterns in stages F1-F4 as compared with stage F0, but only the reduced level of miR-122 in stage F4 was statistically significant (P < 0.04). When analyzing miRNA expression in relation to fibrosis, levels of miR-122 and miR-221 showed negative correlations with fibrosis stage, and miR-122 was found to correlate negatively and miR-224 positively with LS values (all P < 0.05). ALT levels displayed a positive correlation with miR-21 (P < 0.04). Negative correlations were observed in the fibrosis samples of mixed etiology between miR-122 and fibrosis stage and LS values (P < 0.05), and in the samples of chronic viral hepatitis, between miR-221 and fibrosis stage (P < 0.01), whereas miR-21 showed positive correlation with ALT values in the samples of autoimmune liver diseases (P < 0.03). The results also revealed a strong correlation between fibrosis stage and LS values (P < 0.01) when etiology of fibrosis was not taken into account.

conclusionReduced expression of miR-122 in advanced fibrosis and its correlation with fibrosis stage and LS values seem to be characteristic of hepatic fibrosis of various etiologies.

Indexed as

Alanine TransaminaseBiomarkersBiopsyDown-RegulationElasticity Imaging TechniquesGenetic MarkersHumansLiverLiver CirrhosisMicroRNAsPredictive Value of TestsRetrospective StudiesSeverity of Illness IndexAlanine TransaminaseBiomarkersGenetic MarkersMicroRNAsMIRN122 microRNA, humanExpressionFibroScanLiver fibrosisMETAVIRmicroRNAmiR-122

Identifiers

PMID26167081
PMCPMC4491968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.